Adicet Bio’s Promising Pipeline and Strategic Focus Drive Buy Rating
I'm PortAI, I can summarize articles.
Analyst Soumit Roy from JonesTrading has maintained a Buy rating on Adicet Bio with a price target of $5.00, citing promising clinical developments and strategic plans. Key updates expected in 2026 include Phase 1 data releases for lupus nephritis and systemic lupus erythematosus, along with a pivotal trial initiation for ADI-001. Positive early results in targeting CAR γδ T cells support the rating, alongside a strong financial position. H.C. Wainwright also issued a Buy rating with a $9.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments